US EditionObesity drug trial and cancer advances lift Roche profit 58%
6 Articles
6 Articles
Swiss pharmaceutical giant Roche posted net profit of 13.8 billion Swiss francs (15 billion euros) last year, up 50 percent from the previous year. Group revenue rose 2 percent to 61.5 billion francs (68.1 billion euros).
The Swiss pharmaceutical company stated that it expects sales growth in the mid-single digits (between 4% and 6%).
After setbacks, the pharmaceutical company can finally come back to research with potential cashier hits, including a cure for breast cancer. However, in terms of prices, Roche's management is questioning Switzerland.
Roche: strong growth in all world regions and a full pipeline in late stage - European Biotechnology Magazine
Roche made a clear statement in 2025. The Basel-based group increased sales by 7% at constant exchange rates to CHF 61.5bn (€67bn) and lifted core operating profit by as much as 13%. For many observers, this represents far more than just a solid set of annual results. The post Roche: strong growth in all world regions and a full pipeline in late stage appeared first on European Biotechnology Magazine.
After a year marked by American threats of customs duties on the pharmaceutical industry, Roche published on Thursday a turnover and a profit increase, despite the pressure of the franc on its resultsDespite a turbulent year 2025 for the pharmaceutical industry, Roche seems to have endured American pressure without too much difficulty. The Basel pharmaceutical giant released on Thursday a turnover increase of 2% (7% at constant exchange rate) to…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
